Editorial for “Preoperative Differentiation of HER2‐Zero and HER2‐Low from HER2‐Positive Invasive Ductal Breast Cancers Using BI‐RADS MRI Features and Machine Learning Modeling”

Journal of Magnetic Resonance ImagingEarly View Editorial Editorial for "Preoperative Differentiation of HER2-Zero and HER2-Low from HER2-Positive Invasive Ductal Breast Cancers Using BI-RADS MRI Features and Machine Learning Modeling" Thais Maria S. Bezerra, Thais Maria S. Bezerra School of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, BrazilSearch for more papers by this authorAlmir G. V. Bitencourt MD, PhD, Corresponding Author Almir G. V. Bitencourt MD, PhD [email protected] orcid.org/0000-0003-0192-9885 Imaging Department, A.C.Camargo Cancer Center, São Paulo, São Paulo, Brazil Alta Excelência Diagnóstica, DASA, São Paulo, São Paulo, BrazilSearch for more papers by this author Thais Maria S. Bezerra, Thais Maria S. Bezerra School of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, BrazilSearch for more papers by this authorAlmir G. V. Bitencourt MD, PhD, Corresponding Author Almir G. V. Bitencourt MD, PhD [email protected] orcid.org/0000-0003-0192-9885 Imaging Department, A.C.Camargo Cancer Center, São Paulo, São Paulo, Brazil Alta Excelência Diagnóstica, DASA, São Paulo, São Paulo, BrazilSearch for more papers by this author First published: 16 May 2024 https://doi.org/10.1002/jmri.29453 Evidence Level: 5 Technical Efficacy: Stage 2 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Smolarz B, Nowak AZ, Romanowicz H. Breast cancer—Epidemiology, classification, pathogenesis and treatment (review of literature). Cancers (Basel) 2022; 14: 2569. 10.3390/cancers14102569 CASPubMedWeb of Science®Google Scholar 2Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest 2010; 28: 963-968. 10.3109/07357907.2010.496759 PubMedWeb of Science®Google Scholar 3Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022; 387: 9-20. 10.1056/NEJMoa2203690 CASPubMedWeb of Science®Google Scholar 4Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO–College of American Pathologists Guideline Update. J Clin Oncol 2023; 41: 3867-3872. 10.1200/JCO.22.02864 CASPubMedWeb of Science®Google Scholar 5Bitencourt AGV, Gibbs P, Rossi Saccarelli C, et al. MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer. EBioMedicine 2020; 61:103042. 10.1016/j.ebiom.2020.103042 PubMedWeb of Science®Google Scholar 6Ramtohul T, Djerroudi L, Lissavalid E, et al. Multiparametric MRI and radiomics for the prediction of HER2-zero, -low, and -positive breast cancers. Radiology 2023; 308:e222646. 10.1148/radiol.222646 PubMedWeb of Science®Google Scholar 7Peng Y, Zhang X, Qiu Y, et al. Development and validation of MRI radiomics models to differentiate HER2-zero, -Low, and -positive breast cancer. Am J Roentgenol 2024; 222:e2330603. https://doi.org/10.2214/AJR.23.30603. 10.2214/AJR.23.30603 PubMedGoogle Scholar 8Zheng S, Yang Z, Du G, et al. Discrimination between HER2-overexpressing, -low-expressing, and -zero-expressing statuses in breast cancer using multiparametric MRI-based radiomics. Eur Radiol 2024; in press. https://doi.org/10.1007/s00330-024-10641-7. 10.1007/s00330-024-10641-7 Web of Science®Google Scholar 9Rogers W, Thulasi Seetha S, Refaee TAG, et al. Radiomics: from qualitative to quantitative imaging. Br J Radiol 2020; 93:20190948. 10.1259/bjr.20190948 PubMedWeb of Science®Google Scholar 10Zhou J, Zhang Y, Miao H, et al. Preoperative differentiation of HER2-zero and HER2-low from HER2-positive invasive ductal breast cancers using BI-RADS MRI features and machine learning modeling. J Magn Reson Imaging 2024. https://doi.org/10.1002/jmri.29447. 10.1002/jmri.29447 Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation